0001477932-17-003817.txt : 20170810
0001477932-17-003817.hdr.sgml : 20170810
20170810180734
ACCESSION NUMBER: 0001477932-17-003817
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170808
FILED AS OF DATE: 20170810
DATE AS OF CHANGE: 20170810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mazur Leonard L
CENTRAL INDEX KEY: 0001463414
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38174
FILM NUMBER: 171022538
MAIL ADDRESS:
STREET 1: C/O CITIUS PHARMACEUTICALS, INC.
STREET 2: 11 COMMERCE DRIVE, 1ST FLOOR
CITY: CRANFORD
STATE: NJ
ZIP: 07016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Citius Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001506251
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273425913
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11 COMMERCE DRIVE
STREET 2: 1ST FLOOR
CITY: CRANFORD
STATE: NJ
ZIP: 07016
BUSINESS PHONE: (908) 967-6676
MAIL ADDRESS:
STREET 1: 11 COMMERCE DRIVE
STREET 2: 1ST FLOOR
CITY: CRANFORD
STATE: NJ
ZIP: 07016
FORMER COMPANY:
FORMER CONFORMED NAME: Trail One, Inc.
DATE OF NAME CHANGE: 20110314
FORMER COMPANY:
FORMER CONFORMED NAME: TrailOne, Inc.
DATE OF NAME CHANGE: 20101119
4
1
form4.xml
FORM 4
X0306
4
2017-08-08-06:00
false
0001506251
Citius Pharmaceuticals, Inc.
CTXR
0001463414
Mazur Leonard L
C//O CITIUS PHARMACEUTICALS, INC.
11 COMMERCE DRIVE, 1ST FLOOR
CRANFORD
NJ
07016
true
true
true
false
Executive Chairman
Common Stock
2017-08-08-06:00
4
P
false
421400
4.125
A
1779663
D
Common Stock
2017-08-08-06:00
4
C
false
1547067
3.09
A
3326730
D
Warrant to Purchase Common Stock
4.125
2017-08-08-06:00
4
P
false
421400
0.01
A
2018-02-08-07:00
2022-08-08-06:00
Common Stock
421400
421400
D
Convertible Promissory Note
3.09
2017-08-08-06:00
4
A
false
1547067
A
2017-08-08-06:00
2017-12-31-07:00
Common Stock
1547067
1547067
D
Convertible Promissory Note
3.09
2017-08-08-06:00
4
C
false
1547067
D
2017-08-08-06:00
2017-12-31-07:00
Common Stock
1547067
0
D
Warrant to Purchase Common Stock
6.15
2019-06-12-06:00
Common Stock
19614
19614
D
Warrant to Purchase Common Stock
9.90
2019-09-30-06:00
Common Stock
3171
3171
D
Warrant to Purchase Common Stock
9.90
2020-01-08-07:00
Common Stock
4984
4984
D
Warrant to Purchase Common Stock
7.50
2020-08-18-06:00
Common Stock
35211
35211
D
Warrant to Purchase Common Stock
7.50
2020-11-02-07:00
Common Stock
20783
20783
D
Warrant to Purchase Common Stock
7.50
2020-11-20-07:00
Common Stock
20664
20664
D
Warrant to Purchase Common Stock
7.50
2021-01-08-07:00
Common Stock
13679
13679
D
Warrant to Purchase Common Stock
7.50
2021-03-14-07:00
Common Stock
4210
4210
D
Warrant to Purchase Common Stock
6.15
2021-03-15-06:00
Common Stock
18106
18106
D
Options to Purchase Common Stock
6.75
2024-09-12-06:00
Common Stock
220000
220000
D
On August 8, 2017, the Reporting Person purchased a five-year warrant to purchase 421,400 shares of the Company's common stock at an exercise price of $4.125 per share. The warrant is fully vested and exercisable six months from August 8, 2017.
On August 8, 2017, the Reporting Person converted $4,710,000 of outstanding convertible promissory notes and accrued interest of $76,240 into shares of common stock at a conversion price per share of $3.09, which was 75% of the price per share paid by investors in the Company's public offering that was completed on August 8, 2017 as set forth in the terms of the convertible promissory notes.
The warrant is fully vested and exercisable immediately.
The option vests as to 40% of the shares of the Company's common stock on September 12, 2014 and 15% of the shares on each of September 12, 2015, March 12 and September 12, 2016 and September 12, 2017. The option was issued pursuant to the Company's 2014 Stock Incentive Plan.
* All numbers reflect a 1-for-15 reverse stock split on June 9, 2017.
/s/ Leonard L. Mazur
2017-08-10-06:00